London
· Delayed Price · Currency is GBP · Price in GBXAQU: MYIG Company Description
Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions.
The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005.
The company also develops MYCO-006 and MYCO-007. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds.
The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020.
Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2013 |
| Industry | Agricultural Production Crops |
| CEO | David Bartch |
Contact Details
Address: 1075 West Georgia Street Vancouver, British Columbia V6E 3C9 Canada | |
| Phone | 604 687 2038 |
| Website | mydecine.com |
Stock Details
| Ticker Symbol | MYIG |
| Exchange | Aquis Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| SIC Code | 0100 |
Key Executives
| Name | Position |
|---|---|
| David Bartch | Chief Executive Officer |
| John Ross | Chief Financial Officer |
| Damon Michaels | Chief Operating Officer |